Trends of low-grade serous ovarian carcinoma in the United States

被引：29

作者：

Matsuo, Koji ^{[1
,2
]}

Machida, Hiroko ^{[3
]}

Grubbs, Brendan H. ^{[4
]}

Sood, Anil K. ^{[5
]}

Gershenson, David M. ^{[5
]}

机构：

[1] Univ Southern Calif, Div Gynecol Oncol, Dept Obstet & Gynecol, 2020 Zonal Ave,IRD520, Los Angeles, CA 90033 USA

[2] Univ Southern Calif, Norris Comprehens Canc Ctr, Los Angeles, CA 90033 USA

[3] Tokai Univ, Dept Obstet & Gynecol, Sch Med, Isehara, Kanagawa, Japan

[4] Univ Southern Calif, Div Maternal Fetal Med, Dept Obstet & Gynecol, Los Angeles, CA 90033 USA

[5] Univ Texas MD Anderson Canc Ctr, Dept Gynecol Oncol & Reprod Med, Houston, TX 77030 USA

来源：

JOURNAL OF GYNECOLOGIC ONCOLOGY | 2018年 / 29卷 / 01期

关键词：

D O I：

10.3802/jgo.2018.29.e15

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

In the United States, ovarian carcinoma remains the most deadly gynecologic malignancy, and approximately 14,000 deaths are projected from the disease in 2017 [1]. Ovarian carcinoma comprises various histologic subtypes based on the cell of origin, with serous carcinoma being the most common subtype. Serous ovarian carcinomas are commonly grouped into 2 types based on histologic characteristics (high-grade and low-grade) [2,3]. Mounting evidence has shown that low-grade serous ovarian carcinoma (LGSOC) has distinct clinical and molecular differences from high-grade serous ovarian carcinoma (HGSOC) [4,5]. Unlike HGSOC, LGSOC is considered a rare tumor and has been understudied due to its low incidence. To date, there have been no population-based reports of LGSOC statistical trends. The objective of our study was to examine the temporal changes in the proportion of LGSOC among women with epithelial ovarian cancer.

引用

页数：5

共 50 条

[1] Trends in the use of neoadjuvant chemotherapy for low-grade serous ovarian cancer in the United States
Silberman, Jason
Bercow, Alexandra
Gockley, Allison Ann
Eisenhauer, Eric L.
Sisodia, Rachel
Randall, Thomas Christopher
Melamed, Alexander
Bregar, Amy
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[2] Trends in the use of neoadjuvant chemotherapy for low-grade serous ovarian cancer in the United States
Silberman, Jason N.
Bercow, Alexandra S.
Gockley, Allison A.
Eisenhauer, Eric L.
Sisodia, Rachel
Randall, Thomas
del Carmen, Marcela G.
Goodman, Annekathryn
Castro, Cesar M.
Melamed, Alexander
Bregar, Amy J.
[J]. GYNECOLOGIC ONCOLOGY, 2023, 175 : 60 - 65
[3] Low-grade Serous Ovarian Carcinoma
Ricciardi, Enzo
Baert, Thais
Ataseven, Beyhan
Heitz, Florian
Prader, Sonia
Bommert, Mareike
Schneider, Stephanie
du Bois, Andreas
Harter, Philipp
[J]. GEBURTSHILFE UND FRAUENHEILKUNDE, 2018, 78 (10) : 972 - 976
[4] The tuba origin of low-grade serous ovarian carcinoma
Kong, Beihua
[J]. INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2013, 32 : S74 - S74
[5] Ovarian low-grade serous carcinoma: A comprehensive update
Diaz-Padilla, Ivan
Malpica, Anais L.
Minig, Lucas
Chiva, Luis M.
Gershenson, David M.
Gonzalez-Martin, Antonio
[J]. GYNECOLOGIC ONCOLOGY, 2012, 126 (02) : 279 - 285
[6] Low-Grade Serous Ovarian Carcinoma: Challenges and Solutions
Patni, Ranu
[J]. INDIAN JOURNAL OF GYNECOLOGIC ONCOLOGY, 2022, 20 (04)
[7] Estrogen signaling in low-grade serous ovarian carcinoma
Tsang, Yvonne T. M.
Ng, Chun Wai Oscar
Gershenson, David
Wong, K-Kwok
[J]. CANCER RESEARCH, 2024, 84 (06)
[8] Immunosuppressive microenvironment in low-grade serous ovarian carcinoma
Wong, Kwong-Kwok
Gershenson, David M.
[J]. CANCER RESEARCH, 2018, 78 (13)
[9] Current concept of low-grade serous ovarian carcinoma
Nakayama, Kentaro
Razia, Sultana
Ishibashi, Tomoka
Kyo, Satoru
[J]. TRANSLATIONAL CANCER RESEARCH, 2024, 13 (01) : 6 - 10
[10] The role of smoking in low-grade serous ovarian carcinoma
Schlumbrecht, M.
Sun, C.
Wong, K.
Broaddus, R.
Gershenson, D.
Bodurka, D.
[J]. GYNECOLOGIC ONCOLOGY, 2010, 116 (03) : S123 - S124

← 1 2 3 4 5 →